KEY TAKEAWAYS
- The study aimed to examine patient demographics, clinical features, treatment approaches, and resultant outcomes.
- The results showed a more favorable prognosis compared to other brain tumor types, especially those originating from WHO grade 1 meningiomas.
Extraneural metastasis meningioma is uncommon and can present clinical challenges due to uncertain prognosis, especially when considering its association with brain cancer.
Gina Watanabe and her team conducted a study that aimed to assess patient demographics, clinical features, treatment approaches, and resultant outcomes.
The study conducted a comprehensive search of PubMed, EMBASE, Scopus, Cochrane, and Web of Science databases from inception to February 23, 2024, following PRISMA guidelines, to identify cases of metastatic meningioma. Selected analyses utilized descriptive statistics, Mann–Whitney U test, Fisher’s exact tests, Kaplan–Meier curves, and log-rank tests.
About 288 patients (52% male) were analyzed, with an average age of 49 years at meningioma diagnosis. Tumors were predominantly WHO grade 1 (38%), followed by grade 2 (36%) and grade 3 (26%). The majority experienced intracranial recurrence (79%), and the mean time to first metastasis was around 8 years. Most cases (65%) showed no change in WHO grade between primary and metastasis.
Primary treatment of metastasis commonly involved surgery (43%), chemotherapy (20%), or no treatment (14%). Half of the patients (50%) were alive at an average follow-up of 3 years post-metastasis. The overall median survival was 36 months for the entire cohort, significantly varying between WHO grade 1 and grade 2/3 meningioma primaries (168 vs. 15 months, P< 0.005).
Metastatic meningioma demonstrated a comparatively favorable prognosis, especially in cases originating from WHO grade 1 tumors, contrasting with other brain tumor types with extra-neural metastasis.
No funding was granted.
Source: https://link.springer.com/article/10.1007/s11060-024-04659-6
Watanabe, G., Young, K., Rauber, E. et al. “A systematic review of extraneural meningioma metastasis: timing, evolution and outlook.” J Neurooncol (2024). https://doi.org/10.1007/s11060-024-04659-6.
